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Abstract
Background: Since early 2015, a large epidemic of Zika Virus (ZIKV) is spreading across South and Central America.
An association between congenital neurological malformations (mainly microcephaly), other neurological
manifestations such as Guillain-Barrè Syndrome, and ZIKV infection is suspected.
Case presentation: Three confirmed cases of ZIKV in travelers returning from Brazil between May 2015 and January
2016 are described. All patients had mild symptoms with no neurological complications.
Conclusions: An increasing awareness among clinicians about this emerging disease is advisable, both for the
need to provide correct additional information to the patients and to travelers, with a special focus on pregnant
women, and for the presence of the competent vector in Southern Europe.
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Background
In May 2015, the first report of autochthonous Zika
Virus (ZIKV) infection has been confirmed in Brazil. The
ZIKV epidemic is rapidly evolving [1, 2] and autochthon-
ous transmission has been also reported out of Latin
American Countries [1, 2]. At the same time, several
imported cases have been described in USA and European
countries [1, 2].
ZIKV disease is caused by a virus of the Flaviviridae
family transmitted to humans by Aedes mosquitoes.
Perinatal transmission has been reported, as well as
human-to-human transmission through blood transfu-
sion and sexual intercourse [3–5].
The main clinical manifestations of ZIKV are low
grade fever (<38.5 ° C), maculopapular rash, headache,
conjunctivitis, myalgia and arthralgia, with possible small
joint swelling. The clinical course is generally lasting 2–
7 days, and, as for other flavivirus infections, a high rate
of asymptomatic infection with ZIKV is expected [2].
Most people full recover without severe complications,
and hospitalisation rate is low, but fatal outcome has
been described in patients with underlying diseases [6].
Furthermore, an unusual increase of congenital malfor-
mation, in particular microcephaly, and Guillain–Barré
syndrome cases, have been reported in areas where ZIKV
epidemic is ongoing. An association with ZIKV epidemic
has been strongly suspected and is under investigation [2].
As the epidemic will continue to extend, an increasing
number of imported cases are expected. In Italy, the risk
for an autochthonous transmission cannot be excluded,
since the competent vector (Aedes albopictus) is present
and it has already caused a large outbreak of Chikun-
gunya (CHIKV) disease in 2007 [7, 8].
We describe three cases of imported ZIKV fever to
Italy, in travelers returning from Brazil, observed at the
Lazzaro Spallanzani National Institute for Infectious
Diseases (INMI), Rome.
This manuscript adheres to CARE guidelines/meth-
odology [9], and the CARE checklist is reported in
Additional file 1.
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A 74-year-old Italian man sought medical attention, as
outpatient, on May 2015, two days after returning from
Fortaleza, North-East of Brazil, where he spent the last
5 months. He reported six days of maculopapular rash,
low-grade fever, significant joint and muscle tenderness,
malaise and bilateral wrists swelling. At the physical exam-
ination, he showed a papular rash spreading to extremities
including the palms. Neurological examination was nor-
mal. All symptoms completely resolved within few days.
The presence of rash guided the laboratory investigations,
and serology for HIV, syphilis, C. psittaci, M. pneumoniae,
CHIKV and Dengue Virus resulted negative for acute in-
fection. Widal serodiagnosis, Quantiferon, and PCR, in
urine specimen, for both N. gonorrhea and C. trachomatis
resulted negative. An indirect immnofluorescence assay
was positive for ZIKV: 1:40 IgM and 1:80 IgG titers, RT-
PCR for Flavivirus genus both in serum and urine and
RT-PCR for Chikungunya in serum sample were negative.
A follow up sample at day 39 after symptoms onset,
showed a 4-fold increase of the anti ZIKV antibodies titer
(1: 160 IgM and 1:320 IgG) and at day 56 the anti ZIKV
antibodies titer was 1:80 IgM and > =1:1280 (see Table 1).
The patient fully recovered with no complications.
Patient 2
On August 2015 a 58-year-old Italian man was admitted
to the Infectious Diseases ward at INMI, because of
febrile illness and maculopapular rash since two days.
He spent holidays in Brazil (Rio De Janeiro) for two
weeks, and returned in Italy 3 days before hospital refer-
ral. At admission, he was febrile (38.5 ° C) and physical
examination showed a maculopapular rash on the trunk
and upper extremities. Routine blood tests including
haemogram and bio-chemical exams were all within nor-
mal ranges. Thick and thin blood smears were negative
for malaria. Serology was negative (<1:20 for both IgM
and IgG) for Chikungunya and Dengue viruses, an indir-
ect immunofluorescence assay (IFA) for ZIKV revealed a
1:40 IgM titer with <1:20 IgG titer. RT-PCR for Flavivi-
rus genus resulted positive both in serum and urine, the
RT-PCR product was sequenced and ZIKV infection
confirmed. During hospitalization the symptoms rapidly
resolved and the patient was discharged at day 5. Follow
up ZIKV serologic testing, one week after discharge,
showed increased specific antibodies titer (1:640 IgM
and > =1:640 IgG) (see Table 1). The patient fully recov-
ered with no complications.
Patient 3
On January 2016 a 36-year-old Italian woman presented
at the Infectious Diseases outpatient department, with a
widespread maculopapular rash covering the trunk,
arms, and legs, started 2 days after returning from a 8-
days vacation in Brazil (Rio de Janeiro and Buzios). The
patient had been vaccinated against Yellow Fever. At
medical examination, no other symptoms and signs
Table 1 Diagnostic data from 3 patients with ZIKV at INMI, Rome [17–20]
Patient 1 Patient 2 Patient 3
At diagnosis (7)* At day 32 (39)* At diagnosis (2)* At day 12 (14)* At diagnosis (3)* Ad day 7 (11)*
ZIKV RT-PCR seruma Negative Not performed Positive Not performed Positive Negative
RT-PCR urinea Negative Not performed Positive Not performed Positive Positive
IgMb 1:40 1:160 1:40 1:640 <1:20 1:80
IgGb 1:80 1:320 <1:20 > = 1:640 <1:20 1:160
NTg <1:20 1:160 Not Performed <1:20 Not Performed 1:40
Dengue Virus RT-PCR serumc Negative Not performed Negative Not performed Negative Not performed
RT-PCR urinec Not performed Not performed Negative Not performed Negative Not performed
IgMd <1:20 Not performed <1:20 Not performed <1:20 Not performed
IgGd <1:20 Not performed <1:20 Not performed 1:20 Not performed
CHIKV RT-PCR serume Negative Not performed Negative Not performed Negative Not performed
IgMf <1:20 Not performed <1:20 Not performed <1:20 Not performed
IgGf <1:20 Not performed <1:20 Not performed <1:20 Not performed
*Numbers in brackets indicate days from symptoms onset
apan-flavivirus NS5 nested RT-PCR (modified from [17]), followed by the amplicons’ sequencing and phylogenetic analyses
b: IgG and IgM in house indirect immunofluorescence assay performed with homemade slides spotted with a mix (1:1) of uninfected and ZIKV (MR766 strain)–infected
Vero E6 cells, according to [18]. IFA titres <1:20 were considered negative
c: CDC DENV-1-4 Real-Time RT-PCR Assay for Detection and Serotype Identification of Dengue Virus (http://www.cdc.gov/dengue/clinicalLab/realTime.html)
d: IgG and IgM indirect immunofluorescence assay Euroimmun Flavivirus Mosaic 2 slides. IFA titres <1:20 were considered negative
e: Real-time RT-PCR targeting the E1 structural protein [19]
f: IgG and IgM indirect immunofluorescence assay Euroimmun Chikungunya virus slides. IFA titres <1:20 were considered negative
g: Neutralisation test (NT) titres <1:20 were considered negative [20]
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were recognized. Laboratory tests showed leukopenia
(leukocyte count 3.5 × 109 cells/L, range 4.00–10.80 × 109
cells/L) with lymphopenia (lymphocytes 11.0 %, range
20.0–40.0 %) only. Pregnancy test was negative. An indir-
ect immunofluorescence assay resulted negative (<1:20 for
both IgM and IgG) for ZIKV and Chikungunya, while IgG
titer for Dengue Virus was weakly positive, probably be-
cause of cross-reactivity with previous yellow fever vaccin-
ation. RT-PCR for Flavivirus genus resulted positive both
in serum and urine, samples were sequenced and ZIKV
was confirmed. The patient received a counseling about
potential of ZIKV sexual transmission, the need to delay a
possible pregnancy and appropriate methods to reduce
this risk. The symptoms resolved spontaneously in one
day. A follow up ZIKV serologic testing, performed at day
11 after symptoms onset was positive for both IgM (1:80)
and IgG (1:160), pan-flavivirus RT-PCR was negative on
serum whereas was still positive on urine (see Table 1).
For all patients, the presence of ZIKV-specific neutra-
lising antibodies in serum samples was also confirmed
by a virus neutralization assay.
Conclusions
At our institution, since May 2015, three cases of ZIKV
from Brazil were diagnosed. The recognition of this in-
fection, in the early stage of the epidemic when only very
few cases have been reported in Europe, required an
high-level of clinical awareness. The inclusion of ZIKV
in the evaluation for arboviral diseases is mandatory to
provide and early diagnosis and a timely notifications to
public health authorities. Indeed, ZIKV infection is char-
acterized by symptoms overlapping those of Dengue and
Chikungunya infections. Moreover, sometimes the pres-
ence of ZIKV antibodies may cause cross-reaction in
diagnostic tests of other flavivirus, and thus the test in-
terpretation require an high-level of expertise [10, 11].
INMI established serological and molecular diagnostics
for ZIKV in February 2014, and included it in the diag-
nostic menu for fever in travelers returning from trop-
ical countries.
This report, especially in the cases of patients 1 and 2
who were identified at the beginning of ZIKV epidemic,
demonstrates that an integrated model combining clin-
ical awareness, updated epidemiological knowledge, and
advanced diagnostic methods, is able to timely identify
patients affected by emerging diseases. This integrated
approach has long been implemented by INMI in facing
emerging and re-emerging diseases [12].
Moreover, the description of these cases is important,
in order to disseminate the knowledge about this dis-
ease. Indeed, the role of clinicians in the ZIKV infections
is not limited to the disease diagnosis and management,
but additional information should be given to the pa-
tients. Increasing evidence supports a link between the
ZIKV infection during pregnancy and the occurrence of
congenital neurological malformations (mainly micro-
cephaly). Consequently, appropriate information should
be given to pregnant women who travelled in endemic
area about their risk and about the correct diagnostic
procedures and surveillance protocols. For the same rea-
son, it is important to advise pregnant women, or
women who are planning a pregnancy, to consider post-
poning travel to endemic areas [13]. Moreover, some re-
ports strongly support the possibility of transmission
through sexual intercourse and blood transfusion: there-
fore, it is also important to inform travellers returning
home from endemic countries to use condom or to
avoid sexual intercourse and, in any case, to avoid blood
and semen donation for at least 6 months [14, 15]. As
the epidemic will continue to spread, and more cases
will be reported, it is possible that some unexpected
clinical findings will emerge and increasing evidences
will contribute to drive the correct indications for the
patients.
The dissemination of appropriate knowledge and diag-
nostic capability about ZIKV is important in Italy, where
the competent vector is present [7, 16]. In fact, in Italy
Aedes mosquitoes sustained an autochthonous outbreak
of CHIKV, with 205 cases in 2007.
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